2026-05-12 21:10:00
Click:
On May 11, 2026, Yu Hua, Member of the Party Leadership Group and Deputy Director of the Fujian Provincial Medical Products Administration (FJMPA), led a delegation to LBE Pharma for a thematic inspection and research visit. The delegation aimed to gain an in-depth understanding of cross-strait (Fujian–Taiwan) cooperation in the pharmaceutical sector and to coordinate solutions to key challenges and bottlenecks.
The delegation was accompanied by Li Jinhua, Director of the Comprehensive and Finance Department of FJMPA; Chen Shuo, Deputy Director of the Fuzhou New Area Government Affairs Office; Lin Zhanghao from the Fuzhou Drug Inspection Office of FJMPA; and Wang Nengbin from the Service and Development Promotion Office of FJMPA. The visit was hosted by Dr. Tseng Weihong, Executive Vice President of LBE Pharma, together with his team.
During the symposium, Dr. Tseng provided a comprehensive overview of the company’s development history, R&D achievements, and future strategic planning. In the subsequent discussion, both sides focused on key topics including end-to-end intellectual property protection, safeguarding pharmaceutical supply chain interests, and drug registration and marketing authorization.
Deputy Director Yu carefully listened to the company’s concerns, provided guidance on resolving relevant issues, and offered targeted suggestions regarding business operations, technological innovation, and regulatory submissions.
Following the discussion, the delegation visited the company’s manufacturing workshops and laboratories to inspect production processes and the quality management system on site. Deputy Director Yu spoke positively of the company’s high-standard quality management system and strong commitment to R&D investment.

More information